Who We Are
BioSpring is a leading industry expert in oligonucleotide science and technology, specializing in high-quality cGMP manufacturing and analytics for commercial programs and clinical phases I-III, in addition to preclinical material supply and diagnostic manufacturing. We are a privately owned company of 555 employees committed to providing expert support through all phases and regulatory filings, including highly flexible and customizable solutions to accelerate therapeutic programs through the entire drug development lifecycle.
Headquartered in the center of Europe, in Frankfurt, Germany, we are an international company with a subsidiary in the United States and a local presence in Japan. Our global clients can rely on our quality and expertise – guided by our passion for innovation and more than 26 years of experience. Our aim is a highly collaborative partnership to unleash the full potential of our clients’ technology – making great strides and breakthroughs possible.
We are driven by our desire for a healthier world.
Restoring hope in patients living with debilitating diseases is our daily motivation to progress novel oligonucleotide-based therapies to their commercial promise.
What We Do
Managing directors Dr. Sylvia Wojczewski and Dr. Hüseyin Aygün recognized the potential of oligonucleotides back in 1997 and thus founded BioSpring.
Today, BioSpring is one of the world's leading Contract Development and Manufacturing Organizations (CDMOs) for nucleic acid manufacturing and analytics. We serve pharma and biotech companies as well as academic institutions around the globe, supporting our clients with nucleic acid services from early discovery to commercial and diagnostic manufacturing.
We have also established ourselves as a market leader in nucleic acids for genome editing applications in the field of cell and gene therapies.
Our expectation is that our products and services are of the highest quality each and every day. We achieve this through technology and rigorous precision, operating in state-of-the-art facilities that are regularly audited and inspected by our industry-leading clients and regulatory authorities. In 2007, we became the first nucleic acid CDMO in Europe to become cGMP-certified.
Learn more about our qualityOligonucleotides are short, synthetically manufactured nucleotide sequences with a length of approx. 2 to 200 bases. They consist of the same building blocks as DNA and RNA, which form the basis of our genetic information. Synthetic nucleic acid therapeutics can be used in a variety of ways. A number of therapeutic nucleic acids are in clinical development. This work focuses primarily on diseases that are currently considered incurable. They can also be used as boosters in vaccinations or for diagnostics.
With our growing, international team, we continue to develop every day in order to consistently offer the best services to our clients. To achieve this, we employ innovative processes and methods in our state-of-the-art facilities and laboratories, always working according to the highest quality standards. At BioSpring, we set our sights high to meet our clients' unique needs – to jointly give patients with diseases new hope by utilizing the potential of oligonucleotide-based drugs. To achieve this we develop client-oriented solutions that combine innovation, quality, and efficiency in order to be able to realize particularly complex projects of all sizes to the highest satisfaction. The outstanding qualifications of our individual employees, as well as their will to give their very best every day for our clients and the health of their patients, are the reason why we are one of the leading CDMOs in the industry. Furthermore, our culturally diverse, highly qualified team and their exceptional commitment to excellence contribute to providing the highest quality and the most efficient solutions. The strength of our corporate culture and outstanding expertise are what make it possible for us to achieve things that were once thought impossible.The BioSpring Team
Our Leadership
Dr. Sylvia Wojczewski and Dr. Hüseyin Aygün are the founders and managing directors of this owner-managed company. They co-founded BioSpring back in 1997 while completing their doctoral studies in chemistry at the Goethe University in Frankfurt, and have led the company to become one of the largest manufacturers of synthetic nucleic acids in the world. It is their tremendous dedication to research, professionalism, and agility that has led BioSpring to this level of success. Dr. Sylvia Wojczewski and Dr. Hüseyin Aygün have the greatest ambition to fully exploit the potential of oligonucleotides for global human health with their clients, and they exemplify this every day.
